Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Ruimait Medical Technology Co., Ltd., particularly in the respiratory health medical device sector [1][2] - As of August 22, the company's stock closed at 96.48 yuan, down 2.89%, with a rolling PE ratio of 48.73 times and a total market capitalization of 8.645 billion yuan [1] - The average PE ratio for the medical device industry is 56.95 times, with a median of 40.49 times, placing Ruimait at the 86th position in the industry ranking [1][2] Group 2 - For the first quarter of 2025, the company reported revenue of 265 million yuan, representing a year-on-year increase of 38.11%, and a net profit of 71.93 million yuan, up 44.11% year-on-year, with a gross profit margin of 49.57% [2] - The company holds a total of 633 domestic patents, including 107 invention patents, 390 utility model patents, and 136 design patents, as well as 202 international patents [1] - The main products of the company include various types of sleep respiratory machines and monitoring devices, indicating a strong focus on innovation and product development in the respiratory health field [1]

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. specializes in the manufacturing of medical devices and consumables in the respiratory health field [1] - The main products include various types of sleep breathing machines, masks, and monitoring devices [1] - The company holds a total of 633 domestic patents, including 107 invention patents and 390 utility model patents, as well as 202 international patents [1] Financial Performance - For Q1 2025, the company reported a revenue of 265 million yuan, representing a year-on-year increase of 38.11% [2] - The net profit for the same period was 71.93 million yuan, showing a year-on-year growth of 44.11% [2] - The gross profit margin stood at 49.57% [2] Market Position - As of August 6, the company's stock closed at 87.34 yuan, with a rolling price-to-earnings (PE) ratio of 44.11 times [1] - The average PE ratio in the medical device industry is 53.93 times, with a median of 37.81 times, placing Ruimait at the 83rd position in the industry ranking [1][2] - The total market capitalization of the company is 7.826 billion yuan [1]

股东方面，截至2025年3月31日，瑞迈特股东户数9118户，较上次增加1481户，户均持股市值35.28万 元，户均持股数量2.76万股。 北京瑞迈特医疗科技股份有限公司的主营业务是呼吸健康领域医疗设备与耗材产品制造。公司的主要产 品是单水平睡眠呼吸机、双水平睡眠呼吸机、双水平肺病呼吸机、P5系列单水平睡眠呼吸机、全脸面 罩、鼻面罩、鼻垫式面罩、睡眠呼吸初筛仪、多导睡眠呼吸监测仪、HT系列高流量湿化氧疗仪、H-80 系列高流量湿化氧疗仪、R系列双水平无创呼吸机。公司拥有633项国内专利，其中国内发明专利107 项、国内实用新型专利390项、国内外观设计专利136项；国际专利202项，其中包括美国专利39项、欧 洲专利30项、欧盟外观专利26项、英国专利46项、土耳其专利12项、日本专利21项、澳大利亚专利6 项、印度专利18项、沙特阿拉伯专利4项。 7月30日，瑞迈特今日收盘86.19元，下跌1.14%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到43.53倍，总市值77.23亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.15倍，行业中值37.48倍，瑞迈特排名 第81 ...

Group 1 - The core viewpoint of the articles highlights the performance and market position of Ruimait Medical Technology Co., Ltd., particularly in the respiratory health medical device sector [1][2] - As of July 25, Ruimait's stock closed at 88.99 yuan, with a 3.60% increase, and a rolling PE ratio of 44.95, marking a new low in 47 days, with a total market capitalization of 7.974 billion yuan [1] - The average PE ratio for the medical device industry is 55.41, with a median of 37.94, placing Ruimait at the 82nd position in the industry ranking [1][2] Group 2 - In the latest quarterly report for Q1 2025, the company reported revenue of 265 million yuan, a year-on-year increase of 38.11%, and a net profit of 71.9314 million yuan, up 44.11%, with a gross profit margin of 49.57% [2] - The company specializes in manufacturing medical devices and consumables in the respiratory health field, with key products including various types of sleep breathing machines and monitoring devices [1] - Ruimait holds a total of 633 domestic patents, including 107 invention patents, 390 utility model patents, and 136 design patents, as well as 202 international patents across various countries [1]

最新一期业绩显示，2025年一季报，公司实现营业收入2.65亿元，同比38.11%；净利润7193.14万元， 同比44.11%，销售毛利率49.57%。 7月7日，瑞迈特今日收盘80.41元，下跌3.28%，滚动市盈率PE（当前股价与前四季度每股收益总和的比 值）达到40.61倍，总市值72.05亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13瑞迈特40.6146.372.4972.05亿行业平均 51.4249.164.50106.60亿行业中值37.4437.842.5151.15亿1九安医疗10.2110.330.80172.35亿2英科医疗 10.4111.230.93164.55亿3新华医疗14.3013.251.1791.67亿4奥美医疗15.3415.031.5855.41亿5振德医疗 15.3614.470.9855.74亿6山东药玻15.4115.461.77145.80亿7康德莱15.7915.801.3134.03亿8九强生物 16.5115.352.0281.78亿9维力医疗16.5717.221.9437.78亿10奥泰生物16.5817.491.3452.89亿 ...

Group 1 - The core business of the company is the manufacturing of medical devices and consumables in the respiratory health field, including various types of sleep breathing machines and monitoring devices [2] - As of the first quarter of 2025, the company reported a revenue of 265 million yuan, representing a year-on-year increase of 38.11%, and a net profit of 71.93 million yuan, with a year-on-year growth of 44.11% [2] - The company's gross profit margin stands at 49.57% [2] Group 2 - The company's current price-to-earnings (PE) ratio is 38.42, while the industry average PE ratio is 48.08, and the industry median is 36.05 [1][3] - The total market capitalization of the company is 6.816 billion yuan [1] - The company ranks 82nd in terms of PE ratio within its industry [1] Group 3 - The company holds a total of 633 domestic patents, including 107 invention patents and 390 utility model patents, as well as 202 international patents [2] - As of the first quarter of 2025, there are 14 institutions holding shares in the company, with a total of 26.9188 million shares and a market value of 2.172 billion yuan [1]